Lyell Immunopharma (LYEL) Research & Development (2020 - 2026)
Lyell Immunopharma recorded quarterly Research & Development of $36.6 million in Q1 2026, down 29.88% quarter-over-quarter from $52.2 million in Q4 2025, and down 15.75% year-over-year from $43.4 million in Q1 2025.
Lyell Immunopharma's Research & Development history runs 7 years deep, the most recent figure standing at $36.6 million for Q1 2026.
- In Q1 2026, Research & Development fell 15.75% year-over-year to $36.6 million; the TTM figure through Mar 2026 stood at $151.8 million (down 11.66% YoY), while the FY2025 annual figure was $158.7 million, down 7.53% from the prior year.
- Research & Development came in at $36.6 million for Q1 2026 at Lyell Immunopharma, down from $52.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $52.2 million in Q4 2025 to a low of $28.2 million in Q3 2025.
- A 5-year average of $41.7 million and a median of $43.2 million in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 97.21% in 2022 and decreased 28.68% in 2025, its largest moves.
- Lyell Immunopharma's Research & Development stood at $38.0 million in 2022, then gained by 23.57% to $47.0 million in 2023, then gained by 3.56% to $48.7 million in 2024, then climbed by 7.26% to $52.2 million in 2025, then retreated by 29.88% to $36.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $36.6 million, $52.2 million, and $28.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Lyell Immunopharma | 373.31 Mn | 373.31 Mn | - | 36.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.60 Mn |
| Dec 31, 2025 | 52.20 Mn |
| Sep 30, 2025 | 28.17 Mn |
| Jun 30, 2025 | 34.86 Mn |
| Mar 31, 2025 | 43.45 Mn |
| Dec 31, 2024 | 48.67 Mn |
| Sep 30, 2024 | 39.50 Mn |
| Jun 30, 2024 | 40.26 Mn |
| Mar 31, 2024 | 43.17 Mn |
| Dec 31, 2023 | 47.00 Mn |
| Sep 30, 2023 | 43.85 Mn |
| Jun 30, 2023 | 47.47 Mn |
| Mar 31, 2023 | 44.63 Mn |
| Dec 31, 2022 | 38.03 Mn |
| Sep 30, 2022 | 41.61 Mn |
| Jun 30, 2022 | 43.72 Mn |
| Mar 31, 2022 | 35.83 Mn |
| Dec 31, 2021 | 19.29 Mn |
| Sep 30, 2021 | 31.43 Mn |
| Jun 30, 2021 | 46.45 Mn |
| Mar 31, 2021 | 41.53 Mn |
| Dec 31, 2020 | 100,000.00 |
| Sep 30, 2020 | 24.50 Mn |
| Jun 30, 2020 | 97.15 Mn |